AstraZeneca (AZN) Gains on CDC Nod

AstraZeneca AZN shares took on 1% to $28.98. The company confirmed that the Centers for Disease Control and Prevention (CDC) has provided its interim recommendation on the use of FluMist® Quadrivalent Live Attenuated Influenza Vaccine in the U.S. for the 2016-2017 influenza season. Share volume was two million, compared to an all-day average of 3.9 million